CardioLogs ECG Analysis Platform vs Tempus ECG-AF
AI Verdict
Choose CardioLogs ECG Analysis Platform if…
Choose CardioLogs ECG Analysis Platform if your practice requires a comprehensive, cloud-based solution for rapid and accurate analysis of diverse ECG data sources, including Holter monitors, smartwatches, and ECG patches. This platform is ideal for automating the detection and diagnosis of a wide range of arrhythmias, supporting efficient workflow in cardiology, emergency medicine, or internal medicine settings for ongoing patient monitoring and immediate diagnostic needs.
View CardioLogs ECG Analysis Platform →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, using standard 12-lead ECGs. This tool is best suited for population health initiatives or primary care settings aiming to stratify risk and guide earlier intervention or closer follow-up for AF prevention, rather than diagnosing existing arrhythmias.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CardioLogs ECG Analysis Platform | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CardioLogs ECG Analysis PlatformTool A's cloud-based SaaS model with multi-device compatibility, including smartwatches and ECG patches, offers greater flexibility and accessibility for various clinical workflows and data sources. Its real-time monitoring and EHR integration further enhance its ease of use across different settings. Tool B is more focused on integration with traditional 12-lead ECG systems within a facility.
Clinical Value
CardioLogs ECG Analysis PlatformBoth tools are FDA-cleared and offer significant clinical value. Tool A provides a broader diagnostic capability for various arrhythmias across multiple device types, aiding in immediate diagnosis and covering a wider range of patient needs. Tool B offers a highly specific, predictive capability for AF risk in a targeted population, which is valuable for proactive patient management but narrower in scope.
Pricing & Value
Tempus ECG-AFTool B explicitly highlights CMS reimbursement availability with specific CPT codes (0764T and 0765T) and a Medicare rate, providing a clear financial pathway for adoption and cost recovery for healthcare providers. While Tool A offers a transparent 'pay per ECG' model, it lacks specific reimbursement information in the provided facts, making its financial value proposition less clear for US providers.
Enterprise Readiness
CardioLogs ECG Analysis PlatformBoth tools demonstrate strong enterprise readiness with HIPAA compliance, FDA clearance, and integration capabilities. However, Tool A's acquisition by Philips, a global leader in healthcare technology, coupled with its ISO/IEC 27001 certified cloud infrastructure, suggests a more robust and globally scalable enterprise solution.
Innovation
CardioLogs ECG Analysis PlatformBoth are innovative in their respective domains. Tool A's ability to integrate and analyze data from a wide range of devices, including consumer wearables like smartwatches, for real-time arrhythmia detection represents significant innovation in data source utilization and diagnostic speed. Tool B's predictive capability for AF risk is also highly innovative, offering a proactive approach to patient care, but Tool A's broader scope of data integration gives it an edge in overall innovation.
Support & Docs
CardioLogs ECG Analysis PlatformTool A, as a Philips solution, benefits from the extensive global support infrastructure, comprehensive documentation, and established customer service channels of a major healthcare technology company. While Tempus AI (Tool B) undoubtedly offers support, the readily available and publicly accessible documentation and support resources for Tool B appear less comprehensive than those provided by Philips.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CardioLogs ECG Analysis Platform | Tempus ECG-AF |
|---|---|---|
| Primary Analysis Focus | Rapid, accurate, and efficient analysis of ECG data for arrhythmia detection and diagnosis. | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Target Patient Population/Use Case | Aids physicians in arrhythmia detection and diagnosis (general). | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| ECG Compatibility | Multi-Device Compatibility (Holter, smartwatches, ECG patches). | FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. |
| Core Technology | AI-Powered ECG Analysis (Deep Neural Networks). | AI-based algorithm. |
| Integration | Integration with EHR Systems. | Integrated into healthcare facility systems. |
Videos
Demos, reviews, and walkthroughs featuring CardioLogs ECG Analysis Platform and Tempus ECG-AF.